Shield Therapeutics

ID/IDA Facts and Figures

Shield Therapeutics plc is registered in England and Wales. 

Default features description for sign up page.

Careers

Partnerships

Overview

Contact and Locations

Leadership

Announcements

Webinars

Media

Portfolio

Publications

Approved Medicine

Corporate Governance

Analysts & Advisors

AIM Rule 26

Stock Information

Investor Overview

Financials

Noto Sans

Maintaining normal iron levels in the blood is essential to the smooth running of multiple metabolic processes and the optimal functioning of the human body.

Insufficient levels of iron, or decreased total iron in the body, is defined as iron deficiency.

Once diagnosed, iron deficiency is typically treated with either generic and/or over the counter oral iron salt products or intravenous (IV) iron therapy. Oral iron salts are usually prescribed as first line treatment for mild to moderate cases. IV therapy, which is less convenient and more costly to administer, is normally used for treatment of more severe cases.

For traditional or conventional oral iron salt products, the clear issues are poor tolerability, inefficient absorption and efficacy, and consequently poor adherence by patients. There is a clear unmet need for a well tolerated and effective oral iron product.